Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that arylhydantoin and arylthiohydantoin derivatives with hydroxybutyl or methyl side-chains showed superior androgen receptor binding affinity and may serve as promising radioiodinated AR ligands.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

Finasteride reduces prostate size and symptoms with few side effects.

In this study, applying case-only trees and random forests to a prostate cancer prevention trial revealed genotypes that may influence the efficacy of finasteride for prostate cancer prevention.

Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.

In this rat study, finasteride treatment significantly reduced body, testis, epididymis, and prostate weights and affected testicular histology, indicating potential negative impacts on testicular function.

Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.

This study found that elevated free testosterone levels may reduce body fat and increase bone density in males, but also raise the risk of prostate cancer, hair loss, and benign prostate hyperplasia.

This study found no significant increase in depression risk associated with taking five-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia, although further studies are needed to confirm these findings.

In this study, Leonuri Herba alkaloids significantly reduced prostate hyperplasia indicators and improved urinary parameters in hormone-induced model rats.

This study found that dutasteride may reduce the likelihood of hospitalization for BPH-related surgery and newly detected prostate cancer, compared to finasteride, and suggests a budgetary benefit.

This study found that finasteride reduced prostate cancer incidence by 30%, with no significant difference in Gleason scores compared to placebo after re-evaluation of pathology and extended follow-up.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

This review discusses the potential severe consequences of androgenic alopecia, including its association with psychosocial distress and an increased risk for certain diseases, and highlights the need for comprehensive medical evaluation.

This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.

This review discusses androgen and antiandrogen studies in COVID-19, noting potential impacts on disease severity and suggesting the need for more data on their effectiveness and safety.

This study identified 8-hydroxy germacrene B from Curcuma aeruginosa as a highly potent in-vitro 5-alpha reductase inhibitor with significant anti-androgenic activity, while exhibiting mild cytotoxicity on prostate cancer cells without affecting human dermal papilla cells at tested concentrations.

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.

This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.

In this case report, the authors describe a partial androgen insensitivity syndrome patient with a novel AR gene mutation, highlighting challenges in gender assignment decisions for infants with partial AIS.

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

This study found that finasteride and its combination with terazosin significantly reduced PSA levels in patients with benign prostatic hyperplasia, whereas terazosin alone showed no clinically significant effect.

Finasteride may cause breast enlargement, low testosterone a risk factor.

This study explored the effects of a 50% hydroalcoholic UPBF extract on BPH in testosterone propionate-induced rats, finding significant improvements in prostate-related parameters and lower urinary tract symptoms at a 200 mg/kg dose, suggesting potential use in BPH management.

This study introduced a new spectrofluorometric method using a synthesized organic fluorophore to effectively analyze darolutamide and thalidomide in pharmaceutical preparations and biofluids.

This study demonstrated that an ethanol extract of Connarus semidecandrus Jack showed potential anti-androgenic alopecia effects in a testosterone-induced model, suggesting a possible treatment option for hair loss.

Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.

This Mendelian randomization study reports that lifelong increased free testosterone in males was associated with improved bone mineral density and body composition but increased risks of prostate cancer, hypertension, and several other conditions.

This study suggests that 5-alpha-reductase inhibitors may reduce the rate of clinical progression in men with low-risk prostate cancer who choose active surveillance.

This article discusses the preparation of tritium-labeled testosterone metabolites and reports no new experimental findings.